[Form 4] BIODESIX INC Insider Trading Activity

Rhea-AI Filing Summary

Biodesix (BDSX) Chief Commercial Officer Kieran O’Kane reported RSU vesting and a related sale on 11/10/2025. He acquired 75 shares of common stock upon RSU vesting (code M) and sold 25 shares at $7.62 to cover taxes upon vesting. Following these transactions, he directly owned 7,362 shares of common stock and held 73 RSUs.

The filing notes all figures reflect the 1-for-20 reverse stock split effective September 15, 2025. The RSUs vest in sixteen successive quarterly installments measured from February 8, 2022, subject to continued service. Prior ownership includes 309 shares purchased under the Employee Stock Purchase Plan on September 2, 2025.

Insider Trade Summary

Net Seller: 25 shares ($191)

Net Sell 3 txns

Insider O'Kane Kieran

Role Chief Commercial Officer

Sold 25 shs ($190.50)

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	75	$0.00	--
Exercise	Common Stock	75	$0.00	--
Sale	Common Stock	25	$7.62	$190.50

Holdings After Transaction: Restricted Stock Units — 73 shares (Direct); Common Stock — 7,387 shares (Direct)

Footnotes (1)

1. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split"). Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Includes 309 shares of the Issuer's Common Stock, as adjusted for the Reverse Stock Split, purchased under the Issuer's Employee Stock Purchase Plan on September 2, 2025. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Kane Kieran

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		M		75(1)	A	(2)	7,387(1)(3)	D
Common Stock	11/10/2025		S(4)		25	D	$7.62	7,362	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	11/10/2025		M			75(1)	(5)	(5)	Common Stock	75(1)	$0	73(1)	D

Explanation of Responses:

1. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").

2. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

3. Includes 309 shares of the Issuer's Common Stock, as adjusted for the Reverse Stock Split, purchased under the Issuer's Employee Stock Purchase Plan on September 2, 2025.

4. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

5. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.